- Home
- SEIC vs PCVX Comparison
SEIC vs PCVX Comparison
Compare SEIC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEIC
- PCVX
- Stock Information
- Founded
- SEIC 1968
- PCVX 2013
- Country
- SEIC United States
- PCVX United States
- Employees
- SEIC N/A
- PCVX N/A
- Industry
- SEIC Investment Bankers/Brokers/Service
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SEIC Finance
- PCVX Health Care
- Exchange
- SEIC Nasdaq
- PCVX Nasdaq
- Market Cap
- SEIC 9.3B
- PCVX 9.6B
- IPO Year
- SEIC N/A
- PCVX 2020
- Fundamental
- Price
- SEIC $71.66
- PCVX $30.65
- Analyst Decision
- SEIC Buy
- PCVX Strong Buy
- Analyst Count
- SEIC 5
- PCVX 9
- Target Price
- SEIC $86.80
- PCVX $136.50
- AVG Volume (30 Days)
- SEIC 941.5K
- PCVX 3.7M
- Earning Date
- SEIC 04-23-2025
- PCVX 05-07-2025
- Dividend Yield
- SEIC 1.32%
- PCVX N/A
- EPS Growth
- SEIC 27.46
- PCVX N/A
- EPS
- SEIC 4.41
- PCVX N/A
- Revenue
- SEIC $2,125,151,000.00
- PCVX N/A
- Revenue This Year
- SEIC $6.35
- PCVX N/A
- Revenue Next Year
- SEIC $5.58
- PCVX N/A
- P/E Ratio
- SEIC $16.25
- PCVX N/A
- Revenue Growth
- SEIC 10.70
- PCVX N/A
- 52 Week Low
- SEIC $62.38
- PCVX $27.66
- 52 Week High
- SEIC $87.25
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- SEIC 43.16
- PCVX 26.64
- Support Level
- SEIC $70.71
- PCVX $28.58
- Resistance Level
- SEIC $74.39
- PCVX $32.72
- Average True Range (ATR)
- SEIC 3.01
- PCVX 3.75
- MACD
- SEIC 0.08
- PCVX 0.12
- Stochastic Oscillator
- SEIC 52.32
- PCVX 29.09
About SEIC SEI Investments Company
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.